Skip to content

Research / Diseases

Glioblastoma

Glioblastoma is a lethal form of brain cancer in which most patients perish within nine to twelve months of diagnosis.

Wild Wyoming violets, the source of the cyclotides Brain Chemistry Labs studies against glioblastoma
Photo: Dr. Paul Alan Cox
Section 01The problem

Surgery and radiation for tumor removal is particularly challenging. The FDA-approved chemotherapy Temozolomide (TMZ) is effective in only fifty percent of cases, with rapid development of resistance among the cancer cells.

Section 02Our work

At Brain Chemistry Labs, we have taken an innovative approach to glioblastoma treatment based on cyclotides, small circular peptides, extracted from violets.

This led to the discovery[1][2] in vitro of several cyclotides that can turbocharge the power of TMZ to kill glioblastoma cells by as much as eightfold.

As these cyclotides are found only in minuscule concentrations in violets, we have commissioned equally effective synthetic versions that can be produced in quantities sufficient for clinical studies.

Currently we are exploring novel ways of integrating advanced techniques in pharmacology, medicinal chemistry, and ethnobotany to specifically target glioblastoma cells within the brain while at the same time leaving healthy brain tissue intact.

Our hope is that violet cyclotides will provide another powerful tool that can prevent development of resistance of glioblastoma cells to current TMZ therapy for both children and adults.

Section 03Future work

Future work will test the effectiveness of cyclotides, after they are shown to be safe, in human clinical trials.

Join us in supporting this highly impactful work.

Our glioblastoma papers

Section 04References
  1. 1.

    Gerlach SL, Metcalf JS, Dunlop RA, Banack SA, Her C, Krishnan VV, et al. Kalata B1 Enhances Temozolomide Toxicity to Glioblastoma Cells. Biomedicines. 2024;12:2216. doi:10.3390/biomedicines12102216

  2. 2.

    Gerlach SL, Dunlop RA, Metcalf JS, Banack SA, Cox PA. Cyclotides Chemosensitize Glioblastoma Cells to Temozolomide. J Nat Prod. 2022;85:34–46. doi:10.1021/acs.jnatprod.1c00595

Stage

In vitro

Violet cyclotides shown in the laboratory to strengthen the standard chemotherapy. Synthetic versions commissioned for clinical studies.

  • SourceViolet cyclotides
  • Partner drugTemozolomide (TMZ)
  • EffectUp to eightfold
  • NextSafety, then human trials
Fund this work
Section 05How cyclotides help

From a violet to a stronger chemotherapy.

Our hope is that violet cyclotides will provide another powerful tool that can prevent development of resistance of glioblastoma cells to current TMZ therapy for both children and adults.

Our glioblastoma papers
01GLIOBLASTOMAMost patients perish withinnine to twelve months02TEMOZOLOMIDE (TMZ)Effective in only fifty percentof cases; resistance develops03VIOLET CYCLOTIDESSmall circular peptides thatturbocharge TMZ up to eightfold04SYNTHETIC VERSIONSCommissioned for clinicalstudies; human trials once safe